Archives: Projects/Publication

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J

Ophthalmic Research Published online DOI: 10.1159/000455235;

2017

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

Lorenz K, Scheller Y, Katharina B, Franz G, Katharina P, Felix B, Crusiefen C, Flach J, Gehring M, Peto T, Silva R, Tal Y, Pfeiffer

Lorenzo et al.Trials (2017);18:128

2017

Comparison of diabetic retinopathy classification using fluorescein angiography and optical coherence tomography angiography.

Comparison of diabetic retinopathy classification using fluorescein angiography and optical coherence tomography angiography.

Comparison of diabetic retinopathy classification using fluorescein angiography and optical coherence tomography angiography.

Soares M, Neves C, Marques IP, Pires I, Schwartz C, Costa MÂ, Santos T, Durbin M, Cunha-Vaz J.

Br J Ophthalmol. 2017 Jan;101(1):62-68. doi: 10.1136/bjophthalmol-2016-309424.

2017

Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial.

Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial.

Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial.

Simão S, Costa MÂ, Sun JK, Cunha-Vaz J, Simó R; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR).

Ophthalmic Res. 2017;57(2):107-117. doi: 10.1159/000450958.

2017

Rastreio da Retinopatia Diabética. Importância do Sistema de Classificação Automática.

Rastreio da Retinopatia Diabética. Importância do Sistema de Classificação Automática.

Rastreio da Retinopatia Diabética. Importância do Sistema de Classificação Automática.

Ribeiro L, Oliveira CM, Neves C, Ramos JD, Ferreira H, Lobo C, Figueira J, Silva R, Cunha-Vaz J

In: Vilela MAP, Putz C, Dantas AM. Retina Clínica. Texto e Atlas. Rio de Janeiro, Cultura Médica, 2016, p.395-411. ISBN 978-85-7006-668-8

2016

Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat Harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis.

Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat Harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis.

Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat Harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis.

Mendes D, Alves C, Batel Marques F.

CNS Drugs. 2016 Oct;30(10):909-29. doi:10.1007/s40263-016-0377-9.

2016
http://link.springer.com/article/10.1007%2Fs40263-016-0377-9

A systematic review of observational studies evaluating costs of adverse drug reactions.

A systematic review of observational studies evaluating costs of adverse drug reactions.

A systematic review of observational studies evaluating costs of adverse drug reactions.

Batel Marques F, Penedones A, Mendes D, Alves C.

Clinicoecon Outcomes Res. 2016 Aug 24;8:413-26. doi:10.2147/CEOR.S115689.

2016
https://www.dovepress.com/a-systematic-review-of-observational-studies-evaluating-costs-of-adver-peer-reviewed-article-CEOR

Differences in VigiBase reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Differences in VigiBase reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Differences in VigiBase reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Sagwa EL, Souverein Pc, Ribeiro I, Leufkens HG, Mantel-Teeuwisse AK.

Pharmacoepidemiol Drug Saf. 2016 Nov 20. doi:10.1002/pds.4125.

2016
http://onlinelibrary.wiley.com/doi/10.1002/pds.4125/abstract

Outcomes from the first 6 years of operation of the Central Portugal Pharmacovigilance Unit.

Outcomes from the first 6 years of operation of the Central Portugal Pharmacovigilance Unit.

Outcomes from the first 6 years of operation of the Central Portugal Pharmacovigilance Unit.

Batel Marques F, Penedones A, Mendes D, Alves C.

J Patient Saf. 2016 Dec 16. doi:10.1097/PTS.0000000000000273.

2016
http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=Ym2Q62vBJj17YlTnBZThzl2tzsCQTr1hSVXnpct56By06TNTfRKx!1080955772!181195628!8091!-1?sid=WKPTLP:landingpage&an=01209203-900000000-99555